High Throughput Screening (HTS) Market to Grow by USD 19.9 Billion (2024-2028), Boosted by Rising R&D Investments, with AI Redefining Market Landscape - Technavio

NEW YORK, Jan. 31, 2025 -- Report with market evolution powered by AI - The global high throughput screening (HTS) market size is estimated to grow by USD 19.9 billion from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of almost 12.12%  during the forecast period. Rise in R and D investments is driving market growth, with a trend towards increasing focus on promotional activities. However, shortage of trained healthcare professionals  poses a challenge. Key market players include Agilent Technologies Inc., Aurora Biomed Inc., Axxam Spa, Beckman Coulter Inc., Bio Rad Laboratories Inc., Biomat Srl, BMG LABTECH GmbH, Charles River Laboratories International Inc., Corning Inc., Danaher Corp., DIANA Biotechnologies s.r.o, HighRes Biosolutions, JSR Life Sciences LLC, Lonza Group Ltd., Merck KGaA, NanoTemper Technologies GmbH, PerkinElmer Inc., Sygnature Discovery Ltd., Tecan Trading AG, and Thermo Fisher Scientific Inc..

Key insights into market evolution with AI-powered analysis. Explore trends, segmentation, and growth drivers- View Free Sample PDF

Market Driver

High-throughput screening (HTS) is a key trend in the life sciences sector, particularly in the areas of drug discovery and research for complex illnesses like cancer and neurological disorders. HTS allows for the rapid testing of large compound libraries using automated equipment such as robotic arms and microplate readers. Data analytics plays a crucial role in HTS, with machine learning and data management systems used to analyze genomic data and chemical databases for target identification. Biotech startups and academic institutions are driving innovation in this field, with pharmaceutical corporations and research organizations collaborating to advance drug development. HTS is also used in stem cell research, toxicology, and open innovation models. HTS service providers offer instruments, software, and consumables to support this research. HTS is transforming the biopharmaceutical industry, enabling precision medicine and the repurposing of existing drugs for new indications. With advancements in technology, HTS is becoming more accessible to a wider range of organizations, including biotechnology startups and clinical trials. Despite these advancements, challenges remain, including false-positive findings and the need for specialized equipment maintenance. Overall, HTS is a vital tool in the global healthcare sector's quest to develop new products and services for the detection and treatment of chronic diseases. 

The High Throughput Screening (HTS) market presents unique challenges for vendors due to its specialized nature and niche end-users. Brand and product visibility play a limited role in sales, and advertising and marketing are restricted. Key players in the industry recognize this issue and are promoting HTS through their websites and additional support materials. Thermo Fisher Scientific, for instance, provides explanatory documents, brochures, and interactive videos on YouTube to help end-users understand the technique better. Despite these efforts, there is a significant lack of awareness about HTS. Vendors must focus on improving their distribution networks to make these products readily available to end-users. 

Request Sample of our comprehensive report now to stay ahead in the AI-driven market evolution!

Market Challenges

• High-throughput screening (HTS) is a crucial process in the biotechnology industry, enabling the rapid identification of potential drug candidates for complex illnesses such as cancer and neurological disorders. The market for HTS is vast and diverse, with players including academic institutions, biotech startups, and pharmaceutical corporations. Challenges in this field include managing large data sets from compound libraries, dealing with false-positive findings, and maintaining specialized equipment. HTS involves the use of automation, robotics, and specialized instruments like microplate readers and high-resolution imaging systems. Data analytics is essential for making sense of the vast amounts of data generated. Machine learning and data management systems help in data organization, retrieval, integration, and storage. HTS is not just limited to pharmaceutical companies but also extends to the global healthcare sector, research organizations, and contract research organizations. Collaborative networks and HTS service providers play a significant role in driving innovation through open innovation models. HTS is also used in stem cell research, toxicology, and drug development. HTS involves various techniques like cell-based assays, lab-on-a-chip, and label-free technology. Biochemical screening and target identification are critical components of the HTS process. Drug repurposing initiatives, such as those from Relay Therapeutics, are gaining popularity in the biopharmaceutical industry due to their potential to bring new drugs to market faster and more cost-effectively. The HTS market is expected to grow significantly due to the increasing focus on precision medicine and the need for new drugs to address chronic diseases. Consumables, software, and services are essential products and services in the HTS market. The use of technology in HTS, such as automation and advanced detection techniques, is transforming the drug discovery process. Despite the challenges, the future of HTS looks promising, with advancements in technology and a growing focus on collaboration and open innovation models. The use of HTS in drug discovery and development is expected to revolutionize the way we approach complex illnesses and bring new treatments to market.
• In today's fast-paced pharmaceutical and biotechnology industries, High Throughput Screening (HTS) has become a crucial tool for discovering new drugs and optimizing existing ones. However, the successful implementation of HTS relies heavily on the availability of skilled personnel. The shortage of trained professionals in this field can lead to non-compliance and improper screening of drug targets. Consequently, product failures and regulatory issues can result in significant financial losses for companies. This issue is particularly prevalent in developing countries, where the healthcare system lacks the necessary workforce to effectively utilize HTS technology. To mitigate this challenge, it is essential for organizations to invest in training and development programs for their staff, ensuring they have the necessary expertise to operate HTS equipment effectively and efficiently.

Discover how AI is revolutionizing market trends- Get your access now!

Segment Overview 

This high throughput screening (HTS) market report extensively covers market segmentation by  

1. Application 
   • 1.1 Target identification and validation
   • 1.2 Primary and secondary screening
   • 1.3 Toxicology assessment
   • 1.4 Stem cell research
2. End-user 
   • 2.1 Pharmaceutical and biotechnology companies
   • 2.2 Academic and research institutes
   • 2.3 CROs
3. Geography 
   • 3.1 North America
   • 3.2 Europe
   • 3.3 Asia
   • 3.4 Rest of World (ROW)

1.1 Target identification and validation-  The global high throughput screening (HTS) market is driven by the increasing need for target identification and validation in drug development. This process involves finding potential therapeutic targets for diseases or conditions without existing treatments or inadequate current options. Early and thorough target identification and validation establish a strong link to clinical trial success. Chronic diseases like cardiovascular diseases, cancer, and respiratory diseases, which have a high global prevalence, fuel the demand for new targets. Additionally, the growing pipeline for biological candidates, outsourcing from pharmaceutical companies, and regulatory agencies' demand for accurate drug and process development details contribute to market expansion. Advanced bioinformatics tools, automated experimental designs, and AI/ML algorithms are enhancing target identification and validation, further boosting the segment's growth. Consequently, these factors are expected to fuel the growth of the target identification and validation segment in the global high throughput screening market during the forecast period.

Download a Sample of our comprehensive report today to discover how AI-driven innovations are reshaping competitive dynamics

Research Analysis

High-throughput screening (HTS) is a critical technology in the global healthcare sector, enabling the rapid and efficient identification of potential drug candidates for complex illnesses such as cancer and neurological disorders. HTS utilizes compound libraries, often containing hundreds of thousands to millions of compounds, which are screened against disease targets using automated systems. These systems include robotic arms, microplate readers, and high-resolution imaging systems. Data analytics plays a crucial role in HTS, with data management systems, data storage, data organization, data retrieval, data integration, and chemical databases essential for processing and interpreting the vast amounts of data generated. Academic institutions, biotech startups, research organizations, and pharmaceutical corporations all contribute to the HTS market, with open innovation models facilitating collaboration and knowledge sharing. Drug repurposing, the process of discovering new uses for existing drugs, is also a significant application of HTS. The market for HTS is expected to grow significantly due to the increasing demand for new and effective treatments for various diseases.

Market Research Overview

High Throughput Screening (HTS) is a critical technology in the life sciences sector, enabling the rapid identification of potential drug candidates for complex illnesses such as cancer and neurological disorders. HTS utilizes compound libraries, automation, and specialized equipment like robotic arms, microplate readers, and high-resolution imaging systems to screen large numbers of compounds against specific targets. Data analytics plays a crucial role in HTS, with machine learning and data management systems used to organize, store, retrieve, integrate, and analyze genomic data and chemical databases. Collaborative networks and HTS service providers facilitate open innovation models and knowledge sharing among academic institutions, biotech startups, pharmaceutical corporations, and research organizations. Drug repurposing initiatives and biopharmaceutical industry leaders are leveraging HTS for precision medicine and target identification, while toxicology and stem cell research also benefit from this technology. The global healthcare sector continues to invest in HTS for drug discovery, clinical trials, and product development, driving the market for instruments, software, and consumables.

Table of Contents:

1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation

• Application
  • Target Identification And Validation
  • Primary And Secondary Screening
  • Toxicology Assessment
  • Stem Cell Research
• End-user
  • Pharmaceutical And Biotechnology Companies
  • Academic And Research Institutes
  • CROs
• Geography
  • North America
  • Europe
  • Asia
  • Rest Of World (ROW)

7 Customer Landscape
8 Geographic Landscape
9 Drivers, Challenges, and Trends
10 Company Landscape
11 Company Analysis
12 Appendix

About Technavio

Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Contacts
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/

This News is brought to you by Qube Mark, your trusted source for the latest updates and insights in marketing technology. Stay tuned for more groundbreaking innovations in the world of technology.